Advertisement

Topics

Latest Biological Patent NewsRSS

21:14 EST 18th January 2017 | BioPortfolio

Hepatitis C-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

LONDON, Jan. 18, 2017 /PRNewswire/ -- DelveInsight's Report, "Hepatitis C-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Hepatitis C Report is to understand the market and pipeline status of the drugs around the...

MYOLYN Submits Application for FDA Clearance of its MyoCycle Device

MYOLYN’s patent-pending functional electrical stimulation (FES) technology automatically customizes muscle stimulation to the individual patient Gainesville, FL (PRWEB) January 18, 2017 MYOLYN, which creates medical technology for people with muscle weakness and paralysis, today announced that it has submitted a 510(k) to the FDA, requesting clearance of the MyoCycle Home and the MyoCycle Pro ...

Oncoinvent Patent Issues in the USA

Oncoinvent announced today that US Patent 9,539,346 entitled ”Radiotherapeutic particles and suspensions” has issued. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide ge...

Mithra Pharmaceuticals Release: Company Announces Us Patent Allowance For The Use Of Estetrol As Emergency Contraceptive

  Life Sciences Jobs   ...

Targazyme Inc. Receives Additional U.S Patent Award Designed to Improve Cell Therapy Clinical Efficacy Outcomes

CARLSBAD, CA--(Marketwired - January 18, 2017) - Targazyme Inc., a clinical stage biopharmaceutical company developing novel enzyme technologies and products to improve clinical efficacy, safety and cost of care outcomes for patients undergoing cancer immunotherapy, stem cell transplantation and regenerative medicine, announced today that the United States Patent & Trademark Office has awarded...

Oncoinvent Patent Issues In The USA

  Life Sciences Jobs   ...

Forward Pharma settled with Biogen on their patent dispute on active ingredient for MS Tecfidera (dimethyl fumarate): Biogen will pay $1.25 billion upfront, level of royalties TBD

Forward Pharma settled with Biogen on their patent dispute on active ingredient for MS Tecfidera (dimethyl fumarate): Biogen will pay $1.25 billion upfront, level of royalties TBD Reporter: Aviva Lev-Ari, PhD, RN   Biogen will pay $1.25 billion upfront, but the level of royalties will be dependent on the interference proceeding hearing decision. The royalty […]

Biogen in $1.25 billion deal with Forward Pharma to protect MS drug

Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion in cash to gain access to the Danish company's intellectual property as it seeks to protect the patent life of its flagship multiple sclerosis drug, Tecfidera. LONDON Carlyle Group has agreed to become the largest shareholder in Johannesburg-based Global Credit Ratings , the U.S. buyout fund said on Tuesday, looking to br...

Cephalogics Awarded a US Patent for Its High-Density Diffuse Optical Tomography System

The Cephalogics HD-DOT system covered by US Patent 9,498,134 B1 collects data to measure tissue oxygenation in the brain and produce images of hemoglobin concentrations over large regions, which provide valuable information about a patient’s brain perfusion status. Core applications include ischemic and hemorrhagic stroke with the intention t...

EyeTracking, Inc. Issued Key Patent

Patent Covers Measuring Attention or Interest in Augmented Reality and Automotive ADAS Systems EyeTracking, Inc. announced today the issuance by the United States Patent Office, of a patent that covers a person’s interest, or attention to objects automatically or manually identified in a video stream. This Smart News Release features m

Biogen settles in Tecfidera patent case

The big biotech is hedging its bets ahead of a court decision in an ongoing patent case with Forward Pharma.

Advanced Proteome Therapeutics Corporation Announces Issuance of U.S. Patent Covering Novel Molecules for the Treatment of Cancer

VANCOUVER, BC--(Marketwired - January 17, 2017) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC) (FRANKFURT: 0E8) is pleased to announce issuance of APC's U.S. Patent Application 14/400,190 titled "Site-Specific Labeling and Targeted Delivery of Proteins for the Treatment of Cancer". The patent covers multiple examples of novel molecular entities, linked p...

Cephalogics Awarded A U.S. Patent For Its High-Density Diffuse Optical Tomography System

  Life Sciences Jobs   ...

EyeTracking Release: Company Issued Key Patent

  Life Sciences Jobs   ...

BestMassage.com Announces PowerLift Logo Trademark Registration

The PowerLift logo for the in-house electric massage table brand from BestMassage.com, the international massage table and supplies warehouse, is registered with the United States Patent and Trademark Office (USPTO). Chicago, IL (PRWEB) January 16, 2017 Many bodyworkers associate the mark of PowerLift with high-quality, innovative electric massage tables from the international massage table and s...

MonoSolRx LLC Release: Company Files Patent Infringement Suit Against BioDelivery

  Life Sciences Jobs   ...

Teva loses challenge to Eli Lilly cancer drug patent

The US Federal Court of Appeals upheld a lower court's decision on cancer treatment Alimta. 

Supreme Court agrees to review biosimilar launch rules

The U.S. Supreme Court has agreed to delve into a contentious patent dispute between Sandoz and Amgen over how quickly biosimilar drugs can come to market.

An IPR Does Not Necessarily Have Standing to Appeal if it Loses

In Phigenix, Inc. v. ImmunoGen, Inc. , [2016-1544] , the Federal Circuit held that Phigenix, the losing petitioner in an IPR, lacked standing to appeal the PTAB's decision that claims 18 of U.S. Patent No.

Osseon Release: Company Receives New Patent

  Life Sciences Jobs   ...

Patent Victory Secures Eli Lilly Hold On Cancer Drug Until 2022

  Life Sciences Jobs   ...

Eli Lilly Release: Patent Victory Locks In Company's Hold On Cancer Drug Alimta Until 2022

  Life Sciences Jobs   ...

Osseon Receives New Patent

SANTA ROSA, Calif., Jan. 12, 2017 /PRNewswire/ -- Osseon announced today that the company has received a new patent for a Steerable and Curvable Cavity Creation System, patent number US 9,510,885. This new device will add to Osseon's line of existing steerable devices of bone augmenting products for treating compression fractures of the spine. The utilization of this new patent, as well as ex...

Patent Victory Secures Lilly Hold on Cancer Drug Until 2022

Click to view a price quote on LLY. Click to research the Drugs industry.

U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent

INDIANAPOLIS, Jan. 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the district court's decision and ruled in the company's favor regarding validity and infringement of the vitamin regimen patent for Alimta® (pemetrexed for injection). In the case of Eli Lilly and Company v. Teva Parenteral Medicines,...

Quick Search
Advertisement
 

review and buy Biological Patent market research data and corporate reports here